New Modeling Data Show the Cologuard® Test Has Detected More Than 623,000 Cancers and Precancers Over Past Decade, Saving U.S. Health Care System $22 Billion

Court Ruling Enables Exact Sciences to Proceed with Lawsuit against Geneoscopy

Exact Sciences Demonstrates Continued Scientific Advancement in Colorectal Cancer Screening with Multiple Data Presentations at DDW^® 2024

Exact Sciences Names Aaron Bloomer as New Chief Financial Officer

Exact Sciences to Present Late-Breaking Data from ASCEND-2 Study Validating Its Investigational Multi-Cancer Early Detection Test at AACR Annual Meeting 2024 

Exact Sciences to Provide Mayo Clinic Patients with Individualized Cancer Tumor Information to inform treatment

Exact Sciences Announces Preliminary Fourth Quarter 2023 Results

Exact Sciences Announces Second-Quarter 2023 Results

EXACT SCIENCES EARNS 2023 GREAT PLACE TO WORK^® CERTIFICATION^™

New Analysis Reinforces Cost-Effectiveness of the Oncotype DX Breast Recurrence Score® Test in Node-Positive Early-Stage Breast Cancer

Exact Sciences Strengthens Evidence Supporting Cologuard® and Oncotype DX® Tests and Deep Oncology Pipeline with Multiple Data Presentations at ASCO 2021

Exact Sciences Applauds Final Task Force Recommendation That Lowers Starting Age for Colorectal Cancer Screening to 45